Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Source: View publication →
In patients with resistant hypertension, the addition of spironolactone was significantly more effective at lowering blood pressure than bisoprolol, doxazosin, or placebo, establishing it as the optimal fourth-line therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
PATHWAY-2 provided definitive, randomized evidence establishing spironolactone as the most effective fourth-line add-on agent for resistant hypertension. Its findings led directly to updates in major international guidelines (e.g., ACC/AHA, ESC/ESH, NICE) to recommend mineralocorticoid receptor antagonists as the standard of care for 'Step 4' therapy. Furthermore, the robust response to spironolactone reinforced the pathophysiological concept that underlying, unresolved sodium retention drives drug-resistant hypertension.
Historical Context
For decades, managing resistant hypertension was largely empirical, relying on trial-and-error additions of alpha-blockers, beta-blockers, or centrally acting agents. In 2014, the SYMPLICITY HTN-3 trial revealed that renal denervation failed to significantly lower blood pressure compared to a sham procedure, deeply disappointing the cardiology community but simultaneously renewing the focus on optimizing pharmacotherapy. Commissioned by the British Hypertension Society to definitively resolve this management void, PATHWAY-2 successfully transformed resistant hypertension care from a guess-work approach to an evidence-based algorithm.
Guided Discussion
High-yield insights from every perspective
Why is an aldosterone antagonist like spironolactone specifically effective in patients who are already taking an ACE inhibitor or ARB and a thiazide-like diuretic?
Key Response
Students need to understand 'aldosterone escape' and volume-dependent hypertension. Despite RAAS blockade by an ACEi or ARB, aldosterone levels can rebound over time. Furthermore, resistant hypertension often features a low-renin, high-volume state, making direct mineralocorticoid receptor blockade highly effective.
Before initiating spironolactone as a fourth-line agent for resistant hypertension based on the PATHWAY-2 trial, what crucial baseline labs and patient factors must you assess, and how do you monitor them?
Key Response
Residents must know that spironolactone increases the risk of hyperkalemia and renal impairment, especially when combined with an ACEi or ARB. Baseline and follow-up potassium and eGFR checks are mandatory. They must also check for pseudo-resistant hypertension, such as medication non-adherence or white-coat effect, prior to escalating therapy.
How does the crossover design of PATHWAY-2 strengthen the conclusion that spironolactone is the superior fourth-line agent, and how does the concept of 'renin profiling' discussed in the study help tailor therapy in resistant hypertension?
Key Response
Crossover design allows patients to serve as their own controls, reducing inter-individual variability in BP response. Fellows should also appreciate that PATHWAY-2 showed baseline plasma renin inversely predicted the BP-lowering response to spironolactone, supporting the theory that resistant hypertension is fundamentally a low-renin, salt-retaining state.
When counseling a male patient with resistant hypertension who experienced severe gynecomastia on spironolactone, what alternative evidence-based strategies from PATHWAY-2 or similar literature can you employ to maintain optimal blood pressure control?
Key Response
Attendings must manage medication adverse effects practically. If spironolactone causes anti-androgenic side effects, switching to eplerenone or amiloride is a direct, evidence-based next step. Alternatively, bisoprolol or doxazosin represent distinct pharmacological classes shown in PATHWAY-2 to have significant efficacy, albeit slightly less than spironolactone on a population level.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PATHWAY-2 trial utilized a double-blind, 4-way crossover design with 12-week treatment cycles. What are the methodological advantages and potential vulnerabilities, such as carry-over effects or differential drop-out rates, of using this complex design in a longitudinal hypertension trial?
Key Response
PhD researchers focus on design validity. A crossover design dramatically increases statistical power and minimizes confounding but risks carry-over effects (which must be mitigated by washout periods or restricting analysis to end-of-cycle data) and high attrition due to the long, demanding study duration. Evaluating the handling of missing data and period effects is critical.
Given that PATHWAY-2 relied on home blood pressure monitoring (HBPM) as its primary endpoint rather than 24-hour ambulatory blood pressure monitoring (ABPM), how might a reviewer critique this choice, and what steps must the authors report to ensure data integrity and mitigate measurement bias?
Key Response
Editors scrutinize endpoint selection. While ABPM is the diagnostic gold standard for resistant hypertension, HBPM is vastly more practical for a multi-cycle crossover trial. Reviewers would demand standardized device use, automated memory to prevent patient reporting bias, and strong correlation with clinic or ABPM secondary endpoints to validate the primary outcome.
In light of PATHWAY-2, how should major hypertension guidelines formally position mineralocorticoid receptor antagonists in their treatment algorithms, and what safety caveats must be explicitly stated alongside this recommendation?
Key Response
As reflected in the 2017 ACC/AHA and 2018 ESC/ESH guidelines, committees must grant a Class I recommendation for adding spironolactone as the preferred fourth-line agent for resistant hypertension based on this robust evidence. However, guidelines must explicitly condition this recommendation on safety thresholds, specifically requiring an eGFR greater than 30 mL/min and baseline potassium under 4.5-5.0 mEq/L.
Clinical Landscape
Noteworthy Related Trials
SYMPLICITY HTN-3 Trial
Tested
Renal-artery denervation
Population
Patients with severe resistant hypertension
Comparator
Sham procedure
Endpoint
Change in office systolic blood pressure at 6 months
PRAGUE-15 Trial
Tested
Renal denervation
Population
Patients with true resistant hypertension
Comparator
Intensified medical therapy (including spironolactone)
Endpoint
Change in 24-hour ambulatory systolic blood pressure at 6 months
ReHOT Trial
Tested
Spironolactone (12.5-50 mg daily)
Population
Patients with true resistant hypertension
Comparator
Clonidine (0.1-0.3 mg twice daily)
Endpoint
24-hour ambulatory blood pressure control
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis